Pasar al contenido principal

INDUCCION DE AUTOFAGIA A TRAVES DE AGONISTAS DOPAMINERGICOS D3, DAT Y NEUROPROTECCION

BFU2013-47242-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD DE LA LAGUNA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake

  • Castro-Hernández, Javier
  • Afonso-Oramas, Domingo
  • Cruz-Muros, Ignacio
  • Salas-Hernández, Josmar
  • Barroso-Chinea, Pedro
  • Moratalla, Rosario
  • Millan, Mark J.
  • González-Hernández, Tomás
The dopamine (DA) transporter (DAT), a membrane glycoprotein expressed in dopaminergic neurons, clears DA from extracellular space and is regulated by diverse presynaptic proteins like protein kinases, α-synuclein, D2 and D3 autoreceptors. DAT dysfunction is implicated in Parkinson's disease and depression, which are therapeutically treated by dopaminergic D2/D3 receptor (D2/D3R) agonists. It is, then, important to improve our understanding of interactions between D3R and DAT. We show that prolonged administration of pramipexole (0.1 mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution. The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R−/−), yet unaffected in mice genetically deprived of D2R (D2R−/−). Pramipexole treatment induced a physical interaction between D3R and DAT, as assessed by co-immunoprecipitation and in situ proximity ligation assay. Furthermore, it promoted the formation of DAT dimers and DAT association with both D2R and α-synuclein, effects that were abolished in D3R−/− mice, yet unaffected in D2R−/− mice, indicating dependence upon D3R. Collectively, these data suggest that prolonged treatment with dopaminergic D3 agonists provokes a reduction in DA reuptake by dopaminergic neurons related to a hitherto-unsuspected modification of the DAT interactome. These observations provide novel insights into the long-term antiparkinson, antidepressant and additional clinical actions of pramipexole and other D3R agonists., This study was supported by the grants BFU2010-21130 and BFU2013-47242-R (Ministerio de Ciencia e Innovación) to T G-H, BFU2010-20664 (Ministerio de Ciencia e Innovación), PNSD, to R M, and the IMBRAIN project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN), funded under the 7th Framework Programme (Capacities). J C-H was supported by a predoctoral fellowship from the Fundación Canaria de Investigación y Salud (ID54), J S-H was partially supported by the Agencia Canaria de Investigación, Innovación y Sociedad de la Información (SE-10/19), and P B-C was supported by a grant from the Campus de Excelencia Internacional (FEDER, ULL, CEI 10/00018-EDU/903/2010).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis

  • Barroso-Chinea, Pedro
  • Luis-Ravelo, D.
  • Fumagallo-Reading, F.
  • Castro-Hernandez, J.
  • Salas-Hernández, Josmar
  • Rodriguez-Nuñez, J.
  • Febles-Casquero, A.
  • Cruz-Muros, Ignacio
  • Afonso-Oramas, Domingo
  • Abreu-González, P.A.G.
  • Moratalla, Rosario
  • Millan, Mark J.
  • González-Hernández, Tomás
Growing evidence shows that autophagy is deficient in neurodegenerative and psychiatric diseases, and that its induction may have beneficial effects in these conditions. However, as autophagy shares signaling pathways with cell death and interferes with protein synthesis, prolonged use of autophagy inducers available nowadays is considered unwise. The search for novel autophagy inducers indicates that DRD2 (dopamine receptor 2)-DRD3 ligands may also activate autophagy, though critical aspects of the action mechanisms and effects of dopamine ligands on autophagy are still unknown. In order to shed light on this issue, DRD2- and DRD3-overexpressing cells and drd2 KO, drd3 KO and wild-type mice were treated with the DRD2-DRD3 agonist pramipexole. The results revealed that pramipexole induces autophagy through MTOR inhibition and a DRD3-dependent but DRD2-independent mechanism. DRD3 activated AMPK followed by inhibitory phosphorylation of RPTOR, MTORC1 and RPS6KB1 inhibition and ULK1 activation. Interestingly, despite RPS6KB1 inhibition, the activity of RPS6 was maintained through activation of the MAPK1/3-RPS6KA pathway, and the activity of MTORC1 kinase target EIF4EBP1 along with protein synthesis and cell viability, were also preserved. This pattern of autophagy through MTORC1 inhibition without suppression of protein synthesis, contrasts with that of direct allosteric and catalytic MTOR inhibitors and opens up new opportunities for G protein-coupled receptor ligands as autophagy inducers in the treatment of neurodegenerative and psychiatric diseases. Abbreviations: AKT/Protein kinase B: thymoma viral proto-oncogene 1; AMPK: AMP-activated protein kinase; BECN1: beclin 1; EGFP: enhanced green fluorescent protein; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; GPCR; G protein-coupled receptor; GFP: green fluorescent protein; HEK: human embryonic kidney; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MAP2K/MEK: mitogen-activated protein kinase kinase; MAPK1/ERK2: mitogen-activated protein kinase 1; MAPK3/ERK1: mitogen-activated protein kinase 3; MDA: malonildialdehyde; MTOR: mechanistic target of rapamycin kinase; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PPX: pramipexole; RPTOR/raptor: regulatory associated protein of MTOR, complex 1; RPS6: ribosomal protein S6; RPS6KA/p90S6K: ribosomal protein S6 kinase A; RPS6KB1/p70S6K: ribosomal protein S6 kinase B1; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1; WT: wild type., This work was supported by the Spanish Ministerio de Economía y Competitividad [BFU2016-77363-R] and Gobierno Autónomo de Canarias [2018-00000034] to T.G.H. D.L.R. was supported by the “Programa Agustín de Betancourt” (Cabildo Insular de Tenerife). F.F.R. and A.F.C. were supported by the Programme Ayudas para contratos predoctorales para la formación de doctores”, Spanish Ministerio de Economía y Competitividad [BES-2014-067781 and BES-2017‐079923, respectively]; Consejería de Educación, Universidades y Sostenibilidad, Gobierno de Canarias [2018-00000034]; Ministerio de Economía, Industria y Competitividad, Gobierno de España [BFU2016-77363-R]; Ministerio de Economía, Industria y Competitividad, Gobierno de España [BES-2014-067781]; Ministerio de Economía, Industria y Competitividad, Gobierno de España [BES-2017‐079923]; Cabildo de Tenerife (ES) [Programa Agustín de Betancourt].